Related to Unigene and GSK Broaden Deal in Anticipation of Phase III Trial in Postmenopausal Osteoporosis

• Isis Pockets $35M Up Front in Deal with GSK Related to Rare Diseases
  
• GSK and Crucell Team Up to Develop a Prime-Boost Malaria Vaccine
  
• GSK Taps Activiomics to Research Inflammatory Signaling Mechanisms
  
• GSK and EyeGate to Evaluate Iontophoresis System for Drug Delivery to Eye Tissues
  
• GSK Pays £73.9M for Nearly 10% Stake in Korean Firm Dong-A
  
• GSK and Prosensa Expand Ongoing Exon-Skipping DMD Therapeutics Alliance
  
• GSK and EDB Pledge $35M to Augment Green Manufacturing in Singapore
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• GSK Taps NCCN to Conduct Cancer Clinical Testing for $4M
  
• Isis Earns $5M Milestone from GSK Five Months into RNA Therapeutics Partnership
  
• GSK Pays FivePrime $15M to Initiate Skeletal Muscle Disorder Collaboration
  
• Amplimmune Gets $23M Up Front from GSK to Develop PD-1-Targeting Drugs
  
• Nabi Scores Another $8M from GSK under MRSA Vaccine Deal
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• Prosensa Earns £7.5M Milestone from GSK through Antisense DMD Drug Deal
  
• GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug
  
• GSK Reports Japanese Clearance for ITP Drug as Partner Ligand Gets $2M in Govt Grants
  
• Phase III Data Leads Intercell to Shelve Late-Stage Traveler’s Diarrhea Vaccine Patch
  
• GSK Pays Impax $11.5M Up Front for Non-U.S. Rights to Late-Stage PD Therapy
  
• GSK to Use BioClinica Tool to Manage Clinical Trials